Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride is the principal extracellular cation and anion, respectively, in the body. It maintains osmotic pressure, fluid balance, and acid-base balance. It is essential for nerve conduction and muscle contraction.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment and prevention of hypovolemia,Replacement of sodium and chloride deficits,Fluid resuscitation in hemorrhagic shock,Maintenance of intravenous lines (IV flush),Diluent for drug administration
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; dose and rate depend on patient's fluid and electrolyte status; typical maintenance: 0.9% Na Cl at 1-2 m L/kg/h.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal half-life is approximately 24-48 hours in healthy individuals, primarily reflecting renal sodium handling and total body sodium pool; significantly prolonged in renal impairment.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Sodium chloride is not metabolized; it is eliminated primarily by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >95% unchanged via glomerular filtration and tubular reabsorption. Fecal/biliary: negligible.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
None (0%). Sodium is a free ion and does not bind to plasma proteins.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Approximately 0.6-0.7 L/kg, representing total body water distribution; clinical meaning: reflects extracellular fluid volume expansion.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: 100% (complete absorption); IV: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No specific dose adjustment; monitor serum sodium and fluid balance in impaired renal function (e GFR <30 m L/min/1.73 m²).
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No adjustment required; use cautiously in cirrhosis with ascites.
No dosage adjustment required for hepatic impairment.
Intravenous infusion; maintenance: 0.9% Na Cl at 100 m L/kg for first 10 kg, 50 m L/kg for next 10 kg, 20 m L/kg for each kg over 20 kg per 24 h.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Use with caution due to increased risk of fluid overload; lower initial infusion rates recommended.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Use with caution in patients with heart failure, renal impairment, edema, or hypertension.,Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy.,Administration of large volumes may cause fluid overload, hypernatremia, or hypochloremia.,Avoid in patients with hypervolemic states or conditions causing sodium retention.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypernatremia,Fluid overload,Severe renal impairment with oliguria or anuria,Hypersensitivity to sodium chloride
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. However, patients should avoid excessive dietary sodium intake while receiving this medication to prevent hypernatremia. Monitor for changes in taste or nausea.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Sodium chloride administered intravenously at physiologic concentrations does not cross the placenta in significant amounts to cause fetal harm. No teratogenic effects are reported in any trimester. Hypertonic solutions may cause maternal electrolyte disturbances with potential secondary fetal effects if used inappropriately.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Sodium chloride is a normal constituent of breast milk. Intravenous administration at usual doses does not significantly alter milk sodium concentration. M/P ratio is not applicable as sodium is endogenously regulated.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dose adjustment required for normal physiologic use. In conditions with altered sodium handling (e.g., preeclampsia, hyperemesis gravidarum), individualize based on serum sodium and volume status. Pregnancy-induced plasma volume expansion does not necessitate dose changes for isotonic sodium chloride.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Monitor serum sodium and chloride levels closely in patients with heart failure, renal impairment, or liver cirrhosis to avoid hypernatremia or fluid overload. Use 0.9% sodium chloride (normal saline) as a first-line crystalloid for resuscitation; avoid 0.45% saline in patients at risk for increased intracranial pressure. The addition of dextrose may be indicated for hypoglycemia or to avoid hemolysis in hypotonic solutions.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution contains salt; tell your doctor if you are on a low-sodium diet.,Report any swelling, shortness of breath, or rapid weight gain during infusion.,Do not consume additional salt tablets or high-sodium foods without medical advice.,Seek immediate help if you experience confusion, muscle twitching, or severe headache.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride is the principal extracellular cation and anion, respectively, in the body. It maintains osmotic pressure, fluid balance, and acid-base balance. It is essential for nerve conduction and muscle contraction.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE IN PLASTIC CONTAINER is: Intravenous infusion; dose and rate depend on patient's fluid and electrolyte status; typical maintenance: 0.9% Na Cl at 1-2 m L/kg/h.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride administered intravenously at physiologic concentrations does not cross the placenta in significant amounts to cause fetal harm. No teratogenic effects are reported. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.